Prostate-Targeted PET Imaging for Prostate Cancer

(P-PET Trial)

This trial tests a new imaging scan called the Prostate-Targeted PET-Scan (P-PET) to evaluate its effectiveness in detecting prostate cancer. It aims to provide clearer prostate images compared to standard whole-body PET scans. Men with prostate cancer or those suspected of having it can participate. Participants will undergo a standard PET scan followed by a P-PET scan to compare results. This trial suits those who can allocate time for both scans. As an unphased trial, it offers participants the chance to contribute to innovative imaging techniques that could enhance prostate cancer detection.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that prostate-targeted PET scans, such as the P-PET under study, are generally safe for most patients. These scans use a small amount of radioactive material to detect prostate cancer, slightly increasing lifetime radiation exposure. However, this scan type is considered safe and is commonly used in medical practice for prostate cancer detection. Safety findings from similar scans, like PSMA PET scans, indicate they are well-tolerated and effective at identifying cancer. Significant negative side effects from these scans have not been reported.¹²³⁴⁵

Researchers are excited about Prostate-Targeted PET Imaging (P-PET) because it offers a new way to visualize prostate cancer more accurately. Unlike traditional PET scans that provide a static image, P-PET uses dynamic imaging to track how the tracer moves over time, potentially revealing more detailed information about cancerous tissues. This could lead to earlier and more precise detection of prostate cancer, which is crucial for effective treatment planning. By enhancing the clarity and accuracy of prostate cancer imaging, P-PET has the potential to improve outcomes for patients.

Research has shown that PSMA PET scans excel at detecting prostate cancer. One study found PSMA PET/CT to be 92.3% accurate in identifying cancer in lymph nodes. This method surpasses regular imaging techniques in detecting cancer spread. It can even identify very small cancerous areas early, potentially aiding in more effective treatment. PSMA PET ranks among the most reliable methods for prostate imaging available today. In this trial, participants will undergo a standard-of-care PET scan, along with additional dynamic and Prostate-Targeted PET (P-PET) imaging, to evaluate its diagnostic accuracy.⁴⁶⁷⁸⁹